NCT03347097

Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme

Status unknown EARLY_PHASE1 Last updated 25 August 2021

What this trial tests

EARLY_PHASE1 trial testing TIL in Glioblastoma Multiforme in 40 participants. Status unknown.

Timeline

1 January 2017

Primary endpoint
1 January 2020

1 December 2021

Quick facts

Lead sponsor	Huashan Hospital
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 January 2017
Primary completion	1 January 2020
Estimated completion	1 December 2021
Sites	1 location across China

Drugs / interventions tested

• TIL
• PD1-TIL — full drug profile →

Conditions studied

• Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →

Sponsor

Huashan Hospital

Who can join

Adults 18 to 70, any sex, with Glioblastoma Multiforme. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

At present, the investigators want to evaluate safety and efficacy of cell therapy based on Tumor-infiltrating T Lymphocyte (TIL）in glioblastoma. Here, we also constructed a transgenic modified TIL cells, stablely express a high-level full-length PD1 antibody (PD1-TIL cells), which can transduce signals to activate T cells and result in tumor killing. In this study, we design two group patients treated with TIL cells and PD1-TIL cells respectively to determine the safety and efficacy of autologous TILs or genetically modified TILs in patients with glioblastoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
   Lin H, Liu C, Hu A, Zhang D, et al · · 2024 · cited 232× · PMID 38720342 · DOI 10.1186/s13045-024-01544-7
2. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
   Choi BD, Maus MV, June CH, Sampson JH. · · 2019 · cited 91× · PMID 30446589 · DOI 10.1158/1078-0432.ccr-18-1625
3. T cell exhaustion in malignant gliomas.
   Watowich MB, Gilbert MR, Larion M. · · 2023 · cited 84× · PMID 36681605 · DOI 10.1016/j.trecan.2022.12.008
4. Immune Checkpoints and Innovative Therapies in Glioblastoma.
   Romani M, Pistillo MP, Carosio R, Morabito A, et al · · 2018 · cited 70× · PMID 30406030 · DOI 10.3389/fonc.2018.00464
5. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
   Kreatsoulas D, Bolyard C, Wu BX, Cam H, et al · · 2022 · cited 53× · PMID 35690784 · DOI 10.1186/s13045-022-01298-0
6. Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma.
   Zhou S, Huang Y, Chen Y, Liu Y, et al · · 2023 · cited 49× · PMID 36702831 · DOI 10.1038/s41467-023-35957-8
7. Pathogenetic Features and Current Management of Glioblastoma.
   Nguyen HM, Guz-Montgomery K, Lowe DB, Saha D. · · 2021 · cited 42× · PMID 33670551 · DOI 10.3390/cancers13040856
8. Tumor-Specific T Cell Activation in Malignant Brain Tumors.
   Mohme M, Neidert MC. · · 2020 · cited 38× · PMID 32117316 · DOI 10.3389/fimmu.2020.00205